Evidence map›Paper›PMID 32839628›Full record

ReviewTetrahedron2020

The evolution of Tamiflu synthesis, 20 years on: Advent of enabling technologies the last piece of the puzzle?

Cloudius R Sagandira, Francis M Mathe, Upenyu Guyo, Paul Watts

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tetrahedron, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Continuous flow asymmetric synthesis of chiral active pharmaceutical ingredients and their advanced intermediates.Green chemistry : an international journal and green chemistry resource : GC · 2021
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Cloudius R SagandiraNelson Mandela University, University Way, Port Elizabeth, 6031, South Africa.
Francis M MatheNelson Mandela University, University Way, Port Elizabeth, 6031, South Africa.
Upenyu GuyoNelson Mandela University, University Way, Port Elizabeth, 6031, South Africa.
Paul WattsNelson Mandela University, University Way, Port Elizabeth, 6031, South Africa.
Nelson Mandela University · ZAMidlands State University · ZW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza is a serious respiratory disease responsible for significant morbidity and mortality due to both annual epidemics and pandemics; its treatment involves the use of neuraminidase inhibitors. (-)-Oseltamivir phosphate (Tamiflu) approved in 1999, is one of the most potent oral anti-influenza neuraminidase inhibitors. Consequently, more than 70 Tamiflu synthetic procedures have been developed to date. Herein, we highlight the evolution of Tamiflu synthesis since its discovery over 20 years ago in the quest for a truly efficient, safe, cost-effective and environmentally benign synthetic procedure. We have selected a few representative routes to give a clear account of the past, present and the future with the advent of enabling technologies.

Indexed as

Enabling technologiesEvolutionInfluenzaTamiflu synthesis

Identifiers

PMID32839628
PMCPMC7382934
OpenAlexW3044538879

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.